Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
Oculis announced FDA IND clearance for its privosegtor development program in acute multiple sclerosis relapses. The company said clinical development will build on the Phase 2 ACUITY trial and the ongoing PIONEER program in optic neuritis.
Why it matters — The clearance enables Oculis to initiate clinical development of privosegtor for acute MS relapses, expanding its neurology program.